2. Cancer
  3. Cancer Drug Resistance

Cancer Drug Resistance

Drug resistance in chemotherapy, radiotherapy, molecular targeted therapy and immunotherapy is one of the main causes of death due to cancer. Gene mutations, non-genetic and epigenetic mechanisms to evade drug actions can promote the occurrence of drug resistance and treatment failure. Simultaneous resistance to multiple drugs with different chemical structures, different mechanisms of action and different targets is known as multidrug resistance (MDR). MDR can be related to a variety of mechanisms, including overexpression of drug efflux pumps(ABC transporter family), decreased drug uptake, mutation/loss of receptors, altered apoptotic pathway, enhanced DNA repair and drug metabolism(glutathione S-transferase, CYP450).

ABC transporters are membrane protein superfamily that can mediate MDR mechanism in many types of cancer. Some members of this superfamily includes MDR-associated protein-1(MRP1/ABCC1), breast cancer resistant proteins(ABCG2/BRCP) and P-glycoprotein(P-gp/ABCB1/MDR1). Among them, P-gp is the most extensively characterized efflux pump of MDR, and plays an important role in many cancers such as breast cancer, human lung cancer, ovarian cancer, and colorectal cancer.

The design of antitumor drugs that are able to evade or reverse MDR is rapidly evolving in the anti-cancer drug discovery field. Nanoparticle-based drug delivery platforms have been widely studied in cancer treatment, and become optimal carriers to reverse the limitations encountered in the use of traditional drug formulations, by influencing/manipulating ABC transporter-associated drug efflux mechanisms.

Productos relacionados con Cancer Drug Resistance (1943):

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-46866
    Isoegomaketone 34348-59-9
    Isoegomaketone is an orally active apoptosis inducer and radiosensitizer. Isoegomaketone regulates multiple key signaling pathways such as PI3K/AKT/mTOR, NF-κB, MAPK, cleaves Caspase family proteins and PARP, and modulates Bax, AIF and endoplasmic reticulum stress proteins. Isoegomaketone also induces autophagy and keratinocyte proliferation, effectively reduces the levels of inflammatory factors and oxidative stress, inhibits adipocyte differentiation, and resensitizes TRAIL-resistant cancer cells. Isoegomaketone can be applied to research related to colorectal cancer, melanoma, lung cancer, prostate cancer, liver cancer, as well as rheumatoid arthritis and obesity.
    Isoegomaketone
  • HY-N6015
    Bacopasaponin C 178064-13-6 99.76%
    Bacopasaponin C is an orally active natural glycoside. Bacopasaponin C can be isolated from Bacopa monniera. Bacopasaponin C inhibits Verapamil (HY-14275)-stimulated P-gp ATPase activity with an IC50 of 57.83 μg/mL. Bacopasaponin C has antitumor activity against sarcomas. Bacopasaponin C has antiparasitic activity against Leishmania donovani.
    Bacopasaponin C
  • HY-151606
    Akt3 degrader 1 2836342-69-7
    Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomesOsimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer.
    Akt3 degrader 1
  • HY-10346
    AV-412 451493-31-5 99.17%
    AV-412 (MP412) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
    AV-412
  • HY-16114
    BNC105 945771-74-4 98.27%
    BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
    BNC105
  • HY-121793
    Roemerine 548-08-3 99.89%
    Roemerine is an alkaloid that has been identified from the leaves of Fibraurea recisa Pierre. Roemerine exhibits antibacterial, anticancer, and antidepressant activities, can reverse the multidrug resistance phenotype in cultured cells, and exerts antibacterial effects by regulating the cAMP signaling pathway. Additionally, Roemerine influences neuronal activity by increasing BDNF protein expression and modulating the serotonergic and glutamatergic systems. Roemerine holds promise for research in the fields of cancer, infections, and neurological diseases.
    Roemerine
  • HY-108640A
    HLI373 dihydrochloride 1782531-99-0 98.5%
    HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents. Antimalarial activity.
    HLI373 dihydrochloride
  • HY-N2334AR
    Glycochenodeoxycholic acid sodium salt (Standard) 16564-43-5
    Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC).
    Glycochenodeoxycholic acid sodium salt (Standard)
  • HY-N11908
    α-Santalol 115-71-9
    α-Santalol (cis-α-Santalol), a naturally occurring sesquiterpene, is an orally active anticancer agent and apoptosis inducer. α-Santalol activates caspase-3 to drive apoptotic processes. >α-Santalol induces apoptosis, decreases cell viability, and causes PARP cleavage in human prostate cancer cells. α-santalol inhibits Akt/Survivin pathway to induce cell death. α-Santalol can be used for the research of prostate cancer and diabetes mellitus.
    α-Santalol
  • HY-N9459
    2-Amino-2-deoxyglucose hydrochloride 1078691-95-8 98.0%
    2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms.
    2-Amino-2-deoxyglucose hydrochloride
  • HY-B0509AR
    Amikacin (Standard) 37517-28-5
    Amikacin (Standard) is the analytical standard of Amikacin. This product is intended for research and analytical applications. Amikacin (BAY 41-6551), a semisynthetic analog of kanamycin, is very active against most gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin (BAY 41-6551) is ototoxic and nephrotoxic.
    Amikacin (Standard)
  • HY-N1408
    trans-Trimethoxyresveratrol 22255-22-7 99.35%
    Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma).
    trans-Trimethoxyresveratrol
  • HY-185280
    Mocertatug rezetecan 3042848-25-6
    Mocertatug rezetecan (HS-20089; GSK5733584) is an antibody-drug conjugate (ADC) targeting B7-H4. Mocertatug rezetecan exhibits activity against platinum-resistant ovarian cancer. Mocertatug rezetecan is used for the research of advanced solid tumors, especially ovarian cancer and triple-negative breast cancer.
    Mocertatug rezetecan
  • HY-137438
    Edralbrutinib 1858206-58-2 99.75%
    Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC50 of 6.70 nM and a Kd of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.
    Edralbrutinib
  • HY-175743
    TYRA-200 2823289-77-4 98.06%
    TYRA-200 is a potent and orally active FGFR2 inhibitor. TYRA-200 inhibits the kinase activity of wild-type FGFR2 and its mutants. TYRA-200 induces significant tumor regression in FGFR2-driven cancer models. TYRA-200 can be used for the research of FGFR2-altered advanced solid tumors, intrahepatic cholangiocarcinoma, and endometrial cancer.
    TYRA-200
  • HY-126251
    CDK9-IN-7 2369981-71-3 98.05%
    CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.
    CDK9-IN-7
  • HY-151517
    SOS1-IN-14 2793405-20-4 99.60%
    SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817).
    SOS1-IN-14
  • HY-137432B
    Avotaciclib hydrochloride 99.75%
    Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer.
    Avotaciclib hydrochloride
  • HY-159613
    PELP1-IN-1 946262-80-2 99.28%
    PELP1-IN-1 is a PELP1 inhibitor and an apoptosis inducer with no cytotoxic activity against non-cancer cell lines. PELP1-IN-1 targets wild-type, mutant and drug-resistant ER+ breast cancer, and promotes PELP1 degradation through the proteasome pathway. As an analog of SMIP34 (HY-169903), PELP1-IN-1 is applicable to the research of estrogen receptor α-positive breast cancer.
    PELP1-IN-1
  • HY-148953
    MTR-106 1639357-93-9 98.21%
    MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer.
    MTR-106